4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide

7 trials 2 recruiting

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

2 Recruiting

5 Completed trials

1 Sponsors

13 Countries

Phase III

Phase II

Phase III: 6 Phase II: 1

Indications tested

Asthma 1 Vitiligo 1

Sponsors using this IMP

All trials

7 total

Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Phase III 13 countries Incyte Corp.
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting

2024-511879-16-00 Phase III 7 countries Incyte Corp.
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 2 (STOP-PN2) Ended

2024-511881-35-00 Phase III 5 countries Incyte Corp.
Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended

2023-507204-31-00 Phase III 12 countries Incyte Corp.
A Study Evaluating the Efficacy and Safety of Povorcitinib (INCB054707) in Adults With Inadequately Controlled Moderate to Severe Asthma Ended

2022-502570-16-01 Phase II 3 countries Incyte Corp.
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501752-29-00 Phase III 9 countries Incyte Corp.
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501753-36-00 Phase III 7 countries Incyte Corp.

Showing 1–7 of 7 trials

← All drugs A–Z